Pivaris BioScience GmbH is a privately held Research & Development company focused on the development of novel peptides to treat viral infections.
|
Mission
Discovery and development of novel anti-infective agents.
|
Research and Development
Viral infections are a global burden with only a limited number of antiviral agents available. Due to increasing resistance formation, there is a continuous need for additional therapeutic options.
A novel, broad-acting antiviral peptide targeting double-stranded DNA viruses such as herpes simplex virus, cytomegalovirus, vaccinia virus, polyomavirus and adenoviruses has been identified. This first-in-class inhibitor is under evaluation for its use in the treatment of infections caused by double-stranded DNA viruses. The proprietary lead candidate of Pivaris BioScience GmbH is also being evaluated on various other virus models, including RNA viruses.
|
Partners & Funding
Scientific Partners
![Externer Link wird in einem neuen Tab oder Fenster geöffnet](https://img-ie.nccdn.net/Shared/Images/blank.gif?V=5c045c22#SYSTEM)
![Externer Link wird in einem neuen Tab oder Fenster geöffnet](https://img-ie.nccdn.net/Shared/Images/blank.gif?V=5c045c22#SYSTEM)
Institute of Virology, Universitätsklinikum Freiburg, Germany
Institute of Virology, Universitätsklinikum Essen, Germany
Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria
Medical University of Graz, Austria
Funding
![](https://0501.nccdn.net/4_2/000/000/071/260/ffg_logo_de_2018_rgb_300-320x137-320x137.jpg)
![](https://0501.nccdn.net/4_2/000/000/078/264/aws_Schrift_links_3Zeilig-480x111-480x111.jpg)
Funded by Austrian Research Promoting Agency (FFG) and PreSeed of BMDW resp., BMVIT, handled by aws